Allostery Investments LP Decreases Stake in KalVista Pharmaceuticals, Inc. $KALV

Key Points

• Allostery Investments LP reduced its stake in KalVista Pharmaceuticals by 4.3%, now holding 458,302 shares worth approximately $5.3 million.
• Several other institutional investors, including Rhumbline Advisers and Corebridge Financial, have also increased their positions in KalVista Pharmaceuticals during the first quarter.
• KalVista Pharmaceuticals reported a significant earnings miss of ($3.69) EPS, which was below analyst expectations of ($0.83).

Allostery Investments LP reduced its stake in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) by 4.3% in the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 458,302 shares of the specialty pharmaceutical company's stock after selling 20,798 shares during the quarter. KalVista Pharmaceuticals makes up 7.6% of Allostery Investments LP's investment portfolio, making the stock its 3rd largest holding. Allostery Investments LP owned approximately 0.92% of KalVista Pharmaceuticals worth $5,289,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in KALV. Wells Fargo & Company MN lifted its holdings in KalVista Pharmaceuticals by 29.1% in the 4th quarter. Wells Fargo & Company MN now owns 20,165 shares of the specialty pharmaceutical company's stock worth $171,000 after purchasing an additional 4,543 shares during the last quarter. Dimensional Fund Advisors LP lifted its holdings in KalVista Pharmaceuticals by 14.7% in the 4th quarter. Dimensional Fund Advisors LP now owns 696,037 shares of the specialty pharmaceutical company's stock worth $5,895,000 after purchasing an additional 89,001 shares during the last quarter. Tower Research Capital LLC TRC lifted its holdings in KalVista Pharmaceuticals by 666.9% in the 4th quarter. Tower Research Capital LLC TRC now owns 6,327 shares of the specialty pharmaceutical company's stock worth $54,000 after purchasing an additional 5,502 shares during the last quarter. Aquatic Capital Management LLC acquired a new position in shares of KalVista Pharmaceuticals during the fourth quarter worth approximately $44,000. Finally, Algert Global LLC acquired a new position in shares of KalVista Pharmaceuticals during the fourth quarter worth approximately $88,000.

KalVista Pharmaceuticals Price Performance

Shares of KALV traded up $0.37 on Monday, reaching $16.19. 478,482 shares of the stock traded hands, compared to its average volume of 784,935. The stock's 50-day moving average price is $13.79 and its 200-day moving average price is $12.66. KalVista Pharmaceuticals, Inc. has a 12 month low of $7.30 and a 12 month high of $16.33. The firm has a market cap of $814.90 million, a price-to-earnings ratio of -4.38 and a beta of -0.10.

KalVista Pharmaceuticals (NASDAQ:KALV - Get Free Report) last released its quarterly earnings data on Thursday, July 10th. The specialty pharmaceutical company reported ($3.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.83) by ($2.86). During the same period in the previous year, the business posted ($1.07) earnings per share. As a group, equities research analysts forecast that KalVista Pharmaceuticals, Inc. will post -3.56 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have recently commented on the company. Leerink Partners upped their price target on KalVista Pharmaceuticals from $18.00 to $20.00 and gave the stock an "outperform" rating in a report on Monday, July 7th. JMP Securities upped their price target on KalVista Pharmaceuticals from $19.00 to $27.00 and gave the stock a "market outperform" rating in a report on Tuesday, July 8th. Finally, HC Wainwright upped their price target on KalVista Pharmaceuticals from $20.00 to $27.00 and gave the stock a "buy" rating in a report on Tuesday, July 8th. One research analyst has rated the stock with a Strong Buy rating and eight have given a Buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Buy" and a consensus price target of $26.29.

Insider Buying and Selling at KalVista Pharmaceuticals

In other KalVista Pharmaceuticals news, CEO Benjamin L. Palleiko sold 32,979 shares of the stock in a transaction on Wednesday, July 9th. The stock was sold at an average price of $15.69, for a total transaction of $517,440.51. Following the completion of the transaction, the chief executive officer directly owned 369,595 shares in the company, valued at $5,798,945.55. This represents a 8.19% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Paul K. Audhya sold 2,942 shares of the stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $13.22, for a total value of $38,893.24. Following the transaction, the insider owned 119,841 shares of the company's stock, valued at $1,584,298.02. This represents a 2.40% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 52,541 shares of company stock valued at $776,813 over the last quarter. Corporate insiders own 4.30% of the company's stock.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).